Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 13
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Role of SARS-CoV-2-specific memory B cells promoting immune protection after booster vaccination in solid organ transplantation

  • Donadeu, Laura|||0000-0002-5089-5047
  • Gómez-Ollés, Susana|||0000-0002-8935-7641
  • Casanova, Franc|||0000-0001-7427-1987
  • Torija, Alba
  • López-Meseguer, Manuel|||0000-0003-2650-9238
  • Boada Pérez, Meritxell|||0000-0002-8774-8593
  • Kervella, Delphine|||0000-0001-8069-6105
  • Crespo, Elena
  • Carrera-Muñoz, Claudia
  • Campos Varela, Isabel|||0000-0001-6597-3151
  • Castells, Lluís|||0000-0002-6672-5931
  • Cortese, Maria Francesca|||0000-0002-4318-532X
  • Esperalba, Juliana|||0000-0003-1326-1341
  • Fernandez-Naval, Candela|||0000-0002-5584-3537
  • Quintero, Jesús|||0000-0002-6456-9031
  • Muñoz, Marina
  • Agüero, Fernando
  • González-Costello, José|||0000-0002-7437-3630
  • Lladó, Laura|||0000-0002-3717-3306
  • Favà, Alexandre|||0000-0003-1664-6001
  • Cañas, Laura
  • de la Hoz-Caballero, María del Mar
  • Meneghini, Maria|||0000-0001-7307-923X
  • Torres, Irina B.|||0000-0003-3304-0810
  • Juvé, Mariona|||0000-0001-8431-3757
  • Hafkamp, Florianne
  • Vila, Marta|||0000-0001-9303-5189
  • González Robles, Alba
  • Buzón, Maria José|||0000-0003-4427-9413
  • Toapanta, Néstor|||0000-0001-5983-6863
  • Zúñiga, José Miguel
  • Monforte, Víctor|||0000-0002-2918-7679
  • Sáez-Giménez, Berta|||0000-0002-9307-728X
  • Len, Oscar|||0000-0002-1819-3141
  • Los-Arcos, Ibai|||0000-0001-8835-2702
  • Miret Alomar, Enric|||0000-0002-6656-5050
  • Ariceta Iraola, Gema|||0000-0003-1763-1098
  • Pardo, Emma|||0000-0001-8703-5457
  • Martínez, Xavier
  • Moreso, Francesc|||0000-0002-7267-3963
  • Bestard Matamoros, Oriol|||0000-0001-9468-7920
Solid organ transplant (SOT) recipients display weak seroconversion and neutralizing antibody (NAb) responses after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and remain at risk of severe coronavirus disease 2019 (COVID-19). While B-cell memory is the hallmark of serological immunity, its role in driving successful vaccine responses and providing immune protection in SOT patients remains unclear. We investigated the function and interplay of SARS-CoV-2-specific memory B cells (mBc), different cytokineproducing T cells, and cross-reactive NAb in driving seroconversion and protection against COVID-19 in two cohorts. First, we studied a large cohort of 148 SOT recipients and 32 immunocompetent individuals who underwent several vaccinations. Subsequently, we assessed 25 SOT patients participating in a randomized controlled trial to compare two different immunosuppressive strategies for allowing successful seroconversion and memory-cell responses after booster vaccination. We corroborate previous findings that B- and T-cell memory responses are weaker and more delayed in SOT patients than in immunocompetent (IC) individuals; however, within the SOT cohort, we found that these responses are relatively stronger and more robust in patients not receiving mycophenolate mofetil (MMF)-based therapies. Anti- spike IgG titers strongly correlated with RBD-specific IgG-producing mBc, with both displaying broad viral cross reactivity. Prebooster SARS-CoV-2-specific mBc and IL-2- producing T cells accurately predicted Nab seroconversion (AUC, 0.828) and protection against severe COVID-19. While switching unresponsive SOT patients from calcineurin inhibitors (CNI)/MMF to a low-exposure CNI/mTOR-i regimen favored wider SARS-CoV-2-specific immune responses after a fourth booster vaccination, preformed RBD-specific mBc predicted NAb seroconversion. Our study adds new insights into the pathobiology of immune memory and highlights the pivotal role of SARS-CoV-2-specific mBc in promoting immune protection inSOT patients.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

COVID-19 Clinical Profile in Latin American Migrants Living in Spain: Does the Geographical Origin Matter?

  • Sampol Sirvent, Julia
  • Espinosa Pereiro, Juan
  • Miarons Font, Marta
  • Bosch Nicolau, Pau
  • Guillen Del Castillo, Alfredo
  • Leguizamo-Martinez, Lina Maria
  • Oliveira Souto, Ines Mercedes
  • Almirante Gragera, Benito
  • Monforte, Arnau
  • Sempere González, Abiu
  • Campos Varela, Isabel
  • Aznar, María Luisa
  • Antón Pagarolas, Andrés
  • Salvador Velez, Fernando M
  • Sánchez Montalvá, Adrián
COVID-19; Latin America; Severity, COVID-19; Amèrica Llatina; Gravetat, COVID-19; América Latina; Gravedad, The aim of this study was to describe and compare the clinical characteristics of hospitalized patients with COVID-19 pneumonia according to their geographical origin. This is a retrospective case-control study of hospitalized patients with confirmed COVID-19 pneumonia treated at Vall d’Hebron University Hospital (Barcelona) during the first wave of the pandemic. Cases were defined as patients born in Latin America and controls were randomly selected among Spanish patients matched by age and gender. Demographic and clinical variables were collected, including comorbidities, symptoms, vital signs and analytical parameters, intensive care unit admission and outcome at 28 days after admission. Overall, 1080 hospitalized patients were registered: 774 (71.6%) from Spain, 142 (13.1%) from Latin America and the rest from other countries. Patients from Latin America were considered as cases and 558 Spanish patients were randomly selected as controls. Latin American patients had a higher proportion of anosmia, rhinorrhea and odynophagia, as well as higher mean levels of platelets and lower mean levels of ferritin than Spanish patients. No differences were found in oxygen requirement and mortality at 28 days after admission, but there was a higher proportion of ICU admissions (28.2% vs. 20.2%, p = 0.0310). An increased proportion of ICU admissions were found in patients from Latin America compared with native Spanish patients when adjusted by age and gender, with no significant differences in in-hospital mortality., Isabel Campos-Varela’s research activity is funded by grant PI19/00330 from Instituto de Salud Carlos III. CIBERehd is supported by Instituto de Salud Carlos III. The work was independent of all funding. This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

High intrapatient variability of tacrolimus exposure associated with poorer outcomes in liver transplantation

  • Dopazo Taboada, Cristina
  • Bilbao Aguirre, Itxarone Izaskun
  • Gomez Gavara, Concepción
  • Caralt Barba, Mireia
  • Castells Fusté, Lluis
  • Moreso Mateos, Francesc
  • Montoro Ronsano, J. Bruno
  • Charco Torra, Ramon
  • Hidalgo Llompart, Ernest
  • Campos Varela, Isabel
  • García García, Sonia
Liver transplantation; Tacrolimus; Liver diseases, Trasplante de hígado; Tacrolimús; Enfermedades del hígado, Trasplantament hepàtic; Tacrolimús; Malalties del fetge, Tacrolimus (TAC) is a dose-dependent immunosuppressor with considerable intrapatient variability (IPV) in its pharmacokinetics. The aim of this work is to ascertain the association between TAC IPV at 6 months after liver transplantation (LT) and patient outcome. This single-center cohort study retrospectively analyzed adult patients who underwent transplantation from 2015 to 2019 who survived the first 6 months with a functioning graft. The primary end point was the patient’s probability of death and the secondary outcome was the loss of renal function between month 6 and the last follow-up. TAC IPV was estimated by calculating the coefficient of variation (CV) of the dose-corrected concentration (C0/D) between the third and sixth months post-LT. Of the 140 patients who underwent LT included in the study, the low-variability group (C0/D CV < 27%) comprised 105 patients and the high-variability group (C0/D CV ≥ 27%) 35 patients. One-, 3-, and 5-year patient survival rates were 100%, 82%, and 72% in the high-variability group versus 100%, 97%, and 93% in the low-variability group, respectively (p = 0.005). Moreover, significant impaired renal function was observed in the high-variability group at 1 year (69 ± 16 ml/min/1.73 m2 vs. 78 ± 16 ml/min/1.73 m2, p = 0.004) and at 2 years post-LT (69 ± 17 ml/min/1.73 m2 vs. 77 ± 15 ml/min/1.73 m2, p = 0.03). High C0/D CV 3–6 months remained independently associated with worse survival (hazard ratio = 3.57, 95% CI = 1.32–9.67, p = 0.012) and loss of renal function (odds ratio = 3.47, 95% CI = 1.30–9.20, p = 0.01). Therefore, high IPV between the third and sixth months appears to be an early and independent predictor of patients with poorer liver transplant outcomes., Isabel Campos-Varela’s research activity is funded by grant PI19/00330 from Instituto de Salud Carlos III. CIBERehd is supported by Instituto de Salud Carlos III. The work was independent of all funding.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The role of liver steatosis as measured with transient elastography and transaminases on hard clinical outcomes in patients with COVID-19

  • Miret Campos Varela, Isabel
  • Villagrasa Vilella, Ares Aurora
  • Simon-Talero Horga, Macarena
  • Riveiro Barciela, Maria del Mar
  • Ventura Cots, Meritxell
  • Álvarez López, Patricia
  • Nordahl, Emilie Anderssen
  • Anton, Adrian
  • Bañares, Juan
  • Barreira Diaz, Ana
  • Biagetti Biagetti, Betina
  • Camps-Relats, Laura
  • Cocera Rodriguez, Raul
  • Dopazo Taboada, Cristina
  • Fernandez Pujol, Andrea
  • Jimenez Hernandez, Cesar
  • Matarín Jiménez, Maria del Mar
  • Jofra, Mariona
  • Gil, Clara
  • Gomez Gavara, Concepción
  • Guevara Cubas, Jorge Alonso
  • Lobo Alvarez, Beatriz
  • Malagelada Prats, Carolina
  • Martínez Campreciós, Joan
  • Pando Rau, Elizabeth
  • Perez-Lopez, Ana
  • Prio, Alba
  • Rivera Esteban, Jesus Manuel
  • Romero, Alba
  • Tasayco Huaman, Stephanie Solange
  • Vidal Gonzalez, Judit
  • Vidal Piñeiro, Laura
  • Minguez Rosique, Beatriz
  • Genescà Ferrer, Joan
  • Ciudin Mihai, Andreea
  • Barber Caselles, Claudia
  • Augustin Recio, Salvador
  • Aguilera Castro, Lara
  • Guagnozzi, Danila
  • Miret Alomar, Enric
  • Pigrau Pastor, Marc
  • Mayorga Ayala, Luis Fernando
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Paràmetre d'atenuació controlat; Lesió hepàtica, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Parámetro de atenuación controlado; Daño hepático, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Controlled attenuation parameter; Liver injury, Liver injury has been widely described in patients with Coronavirus disease 2019 (COVID-19). We aimed to study the effect of liver biochemistry alterations, previous liver disease, and the value of liver elastography on hard clinical outcomes in COVID-19 patients. We conducted a single-center prospective observational study in 370 consecutive patients admitted for polymerase chain reaction (PCR)-confirmed COVID-19 pneumonia. Clinical and laboratory data were collected at baseline and liver parameters and clinical events recorded during follow-up. Transient elastography [with Controlled Attenuation Parameter (CAP) measurements] was performed at admission in 98 patients. All patients were followed up until day 28 or death. The two main outcomes of the study were 28-day mortality and the occurrence of the composite endpoint intensive care unit (ICU) admission and/or death. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were elevated at admission in 130 patients (35%) and 167 (45%) patients, respectively. Overall, 14.6% of patients presented the composite endpoint ICU and/or death. Neither ALT elevations, prior liver disease, liver stiffness nor liver steatosis (assessed with CAP) had any effect on outcomes. However, patients with abnormal baseline AST had a higher occurrence of the composite ICU/death (21% versus 9.5%, p = 0.002). Patients ⩾65 years and with an AST level > 50 U/ml at admission had a significantly higher risk of ICU and/or death than those with AST ⩽ 50 U/ml (50% versus 13.3%, p < 0.001). In conclusion, mild liver damage is prevalent in COVID-19 patients, but neither ALT elevation nor liver steatosis influenced hard clinical outcomes. Elevated baseline AST is a strong predictor of hard outcomes, especially in patients ⩾65 years., The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: JG is a recipient of a Research Intensification grant from the Instituto de Salud Carlos III, Spain. MST and MVC are recipients of a Juan Rodés grant from the Instituto de Salud Carlos III. The work was partially funded by grants PI17/00310, PI18/00947, PI18/00961, and PI19/00330 from Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF, “Investing in your future” – Una manera de hacer Europa). CIBERehd is supported by Instituto de Salud Carlos III. The work was independent of all funding.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Spontaneous portosystemic shunt embolization in liver transplant recipients with recurrent hepatic encephalopathy

  • Álvarez López, Patricia
  • Quiroga Gómez, Sergi
  • Díez Miranda, Iratxe
  • Charco Torra, Ramon
  • Simon-Talero Horga, Macarena
  • Castells Fusté, Lluis
  • Campos Varela, Isabel
Angiogenesis; Portal hypertension; Collateral vessels, Angiogénesis; Hipertensión portal; Vasos colaterales, Angiogènesi; Hipertensió portal; Vasos col·laterals, Introduction and objectives Spontaneous portosystemic shunts (SPSS) are a common cause of recurrent hepatic encephalopathy (HE). Shunt occlusion is an effective and safe procedure when performed in patients with cirrhosis and preserved liver function. We aimed to describe our experience with SPSS embolization after liver transplantation (LT). Patients We identified five patients who underwent SPSS embolization after LT. Clinical, biochemical and technical procedure data were collected. Results At presentation, all patients had developed graft cirrhosis and HE after LT. Median Model for End-stage Liver Disease (MELD) at embolization was 9 (range 7-12), median Child-Pugh was 8 (range 7-9). Splenorenal and mesocaval shunt were the most frequent types of SPSS found. Three patients have been completely free of HE. Of the two patients who had HE recurrence after embolization, one patient had two episodes of HE which was controlled well with medications. The other patient required three embolizations because of recurrent HE. Median follow-up was 4.4 years (range 1.0-5.0) and MELD score at last follow up was 13 (range 10-18) and median Child-Pugh score B, 7 points (range 5-12). Conclusions SPSS can be considered as a cause of HE after LT. SPSS embolization is feasible and safe in LT recipients., Isabel Campos-Varela's research activity is funded by grant PI19/00330, funded by Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF) - A way to build Europe. Macarena Simón-Talero is a recipient of the Juan Rodés grant JR17/00029 from Instituto de Salud Carlos III, Spain. CIBERehd is supported by Instituto de Salud Carlos III. The work was independent of all funding.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The role of liver steatosis as measured with transient elastography and transaminases on hard clinical outcomes in patients with COVID-19

  • Campos Varela, Isabel|||0000-0001-6597-3151
  • Villagrasa, Ares|||0000-0003-0928-0427
  • Simón Talero, Macarena|||0000-0002-1409-3936
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Ventura-Cots, Meritxell|||0000-0001-9513-2855
  • Aguilera-Castro, Lara
  • Álvarez-López, Patricia|||0000-0003-4227-1987
  • Nordahl, Emilie Anderssen
  • Anton, Adrian
  • Bañares, Juan|||0000-0002-1966-1947
  • Barber Caselles, Claudia|||0000-0003-4711-2731
  • Barreira-Diaz, Ana|||0000-0002-4368-8939
  • Biagetti, Betina|||0000-0002-8837-4343
  • Camps-Relats, Laura
  • Ciudin, Andreea|||0000-0001-5622-0203
  • Cocera, Raul
  • Dopazo, Cristina|||0000-0001-6274-5911
  • Fernandez, Andrea
  • Jiménez, Cesar|||0000-0003-2455-2048
  • Jiménez, María M.
  • Jofra Castells, Mariona|||0000-0002-3034-4985
  • Gil, Clara
  • Gómez Gavara, Concepción|||0000-0001-8312-3273
  • Guanozzi, Danila
  • Guevara, Jorge A.
  • Lobo Álvarez, Beatriz|||0000-0003-3391-7125
  • Malagelada Prats, Carolina|||0000-0001-7097-1492
  • Martínez-Campreciós, Joan|||0000-0002-8899-8447
  • Mayorga, Luis
  • Miret Alomar, Enric|||0000-0002-6656-5050
  • Pando, Elizabeth|||0000-0001-6898-5502
  • Pérez-Lopez, Ana
  • Pigrau Pastor, Marc|||0000-0001-6801-3017
  • Prió, Alba
  • Rivera Esteban, Jesús|||0000-0003-4357-8817
  • Romero, Alba
  • Tasayco, Staphanie|||0000-0001-7867-349X
  • Vidal-Gonzalez, Judit
  • Vidal Piñeiro, Laura|||0000-0003-3757-3323
  • Mínguez Rosique, Beatriz|||0000-0002-7276-9666
  • Augustin Recio, Salvador|||0000-0002-3515-9033
  • Genescà Ferrer, Joan|||0000-0002-0831-8422
Liver injury has been widely described in patients with Coronavirus disease 2019 (COVID-19). We aimed to study the effect of liver biochemistry alterations, previous liver disease, and the value of liver elastography on hard clinical outcomes in COVID-19 patients. We conducted a single-center prospective observational study in 370 consecutive patients admitted for polymerase chain reaction (PCR)-confirmed COVID-19 pneumonia. Clinical and laboratory data were collected at baseline and liver parameters and clinical events recorded during follow-up. Transient elastography [with Controlled Attenuation Parameter (CAP) measurements] was performed at admission in 98 patients. All patients were followed up until day 28 or death. The two main outcomes of the study were 28-day mortality and the occurrence of the composite endpoint intensive care unit (ICU) admission and/or death. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were elevated at admission in 130 patients (35%) and 167 (45%) patients, respectively. Overall, 14.6% of patients presented the composite endpoint ICU and/or death. Neither ALT elevations, prior liver disease, liver stiffness nor liver steatosis (assessed with CAP) had any effect on outcomes. However, patients with abnormal baseline AST had a higher occurrence of the composite ICU/death (21% versus 9.5%, p = 0.002). Patients ⩾65 years and with an AST level.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Safety of Drugs Used during the First Wave of COVID-19, A Hospital-Registry-Based Study

  • Aguilera, Cristina|||0000-0002-7985-7327
  • Danés Carreras, Immaculada|||0000-0002-8711-9666
  • Guillen Benitez, Elena|||0000-0002-5687-5549
  • Vimes, Alba
  • Bosch Ferrer, Montserrat|||0000-0001-7590-9073
  • Cereza García, Gloria|||0000-0002-0328-100X
  • Sánchez Montalvá, Adrián|||0000-0002-2194-5447
  • Campos Varela, Isabel|||0000-0001-6597-3151
  • Miarons, Marta|||0000-0001-7847-1580
  • Mestre Torres, Jaume|||0000-0001-6612-221X
  • Agustí Escasany, M. Antònia|||0000-0003-4594-1122
The emergency of the coronavirus disease 2019 (COVID-19) pandemic led to the off-label use of drugs without data on their toxicity profiles in patients with COVID-19, or on their concomitant use. Patients included in the COVID-19 Patient Registry of a tertiary hospital during the first wave were analyzed to evaluate the adverse drug reactions (ADRs) with the selected treatments. Twenty-one percent of patients (197 out of 933) had at least one ADR, with a total of 240 ADRs. Patients with ADRs were more commonly treated with multiple drugs for COVID-19 infection than patients without ADRs (p < 0.001). They were younger (median 62 years vs. 70.1 years; p < 0.001) and took less medication regularly (69.5% vs. 75.7%; p = 0.031). The most frequent ADRs were gastrointestinal (67.1%), hepatobiliary (10.8%), and cardiac disorders (3.3%). Drugs more frequently involved included lopinavir/ritonavir (82.2%), hydroxychloroquine (72.1%), and azithromycin (66.5%). Although most ADRs recovered without sequelae, fatal cases were described, even though the role of the disease could not be completely ruled out. In similar situations, efforts should be made to use the drugs in the context of clinical trials, and to limit off-label use to those drugs with a better benefit/risk profile in specific situations and for patients at high risk of poor disease prognosis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

High intrapatient variability of tacrolimus exposure associated with poorer outcomes in liver transplantation

  • Dopazo, Cristina|||0000-0001-6274-5911
  • Bilbao, Itxarone|||0000-0002-7389-395X
  • García, Sonia
  • Gómez Gavara, Concepción|||0000-0001-8312-3273
  • Caralt, Mireia|||0000-0002-6110-8280
  • Campos Varela, Isabel|||0000-0001-6597-3151
  • Castells, Lluís|||0000-0002-6672-5931
  • Hidalgo i Llompart, Ernest|||0000-0002-4680-9580
  • Moreso, Francisco
  • Montoro, Bruno
  • Charco, Ramon|||0000-0001-9709-6288
Tacrolimus (TAC) is a dose-dependent immunosuppressor with considerable intrapatient variability (IPV) in its pharmacokinetics. The aim of this work is to ascertain the association between TAC IPV at 6 months after liver transplantation (LT) and patient outcome. This single-center cohort study retrospectively analyzed adult patients who underwent transplantation from 2015 to 2019 who survived the first 6 months with a functioning graft. The primary end point was the patient's probability of death and the secondary outcome was the loss of renal function between month 6 and the last follow-up. TAC IPV was estimated by calculating the coefficient of variation (CV) of the dose-corrected concentration (C/D) between the third and sixth months post-LT. Of the 140 patients who underwent LT included in the study, the low-variability group (C/D CV < 27%) comprised 105 patients and the high-variability group (C/D CV ≥ 27%) 35 patients. One-, 3-, and 5-year patient survival rates were 100%, 82%, and 72% in the high-variability group versus 100%, 97%, and 93% in the low-variability group, respectively (p = 0.005). Moreover, significant impaired renal function was observed in the high-variability group at 1 year (69 ± 16 ml/min/1.73 m 2 vs. 78 ± 16 ml/min/1.73 m 2, p = 0.004) and at 2 years post-LT (69 ± 17 ml/min/1.73 m 2 vs. 77 ± 15 ml/min/1.73 m 2, p = 0.03). High C/D CV 3-6 months remained independently associated with worse survival (hazard ratio = 3.57, 95% CI = 1.32-9.67, p = 0.012) and loss of renal function (odds ratio = 3.47, 95% CI = 1.30-9.20, p = 0.01). Therefore, high IPV between the third and sixth months appears to be an early and independent predictor of patients with poorer liver transplant outcomes.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

COVID-19 Clinical Profile in Latin American Migrants Living in Spain, Does the Geographical Origin Matter?

  • Sempere González, Abiu|||0000-0002-3347-9383
  • Salvador Velez, Fernando Maria|||0000-0002-0546-1354
  • Monforte-Pallarés, Arnau|||0000-0002-5468-3885
  • Sampol, Júlia|||0000-0003-0939-7772
  • Espinosa-Pereiro, Juan|||0000-0002-7238-8337
  • Miarons, Marta|||0000-0001-7847-1580
  • Bosch-Nicolau, Pau|||0000-0002-7435-1829
  • Guillén-Del-Castillo, Alfredo|||0000-0003-0626-507X
  • Aznar, Maria Luisa|||0000-0001-9223-7790
  • Campos Varela, Isabel|||0000-0001-6597-3151
  • Sánchez Montalvá, Adrián|||0000-0002-2194-5447
  • Leguízamo-Martínez, Lina María
  • Oliveira, Ines|||0000-0001-6018-5797
  • Antón Pagarolas, Andrés, 1976-|||0000-0002-1476-0815
  • Almirante Gragera, Benito|||0000-0002-1189-2361
The aim of this study was to describe and compare the clinical characteristics of hospitalized patients with COVID-19 pneumonia according to their geographical origin. This is a retrospective case-control study of hospitalized patients with confirmed COVID-19 pneumonia treated at Vall d'Hebron University Hospital (Barcelona) during the first wave of the pandemic. Cases were defined as patients born in Latin America and controls were randomly selected among Spanish patients matched by age and gender. Demographic and clinical variables were collected, including comorbidities, symptoms, vital signs and analytical parameters, intensive care unit admission and outcome at 28 days after admission. Overall, 1080 hospitalized patients were registered: 774 (71.6%) from Spain, 142 (13.1%) from Latin America and the rest from other countries. Patients from Latin America were considered as cases and 558 Spanish patients were randomly selected as controls. Latin American patients had a higher proportion of anosmia, rhinorrhea and odynophagia, as well as higher mean levels of platelets and lower mean levels of ferritin than Spanish patients. No differences were found in oxygen requirement and mortality at 28 days after admission, but there was a higher proportion of ICU admissions (28.2% vs. 20.2%, p = 0.0310). An increased proportion of ICU admissions were found in patients from Latin America compared with native Spanish patients when adjusted by age and gender, with no significant differences in in-hospital mortality.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

The role of liver steatosis as measured with transient elastography and transaminases on hard clinical outcomes in patients with COVID-19

  • Miret Campos Varela, Isabel
  • Villagrasa Vilella, Ares Aurora
  • Simon-Talero Horga, Macarena
  • Riveiro Barciela, Maria del Mar
  • Ventura Cots, Meritxell
  • Álvarez López, Patricia
  • Nordahl, Emilie Anderssen
  • Anton, Adrian
  • Bañares, Juan
  • Barreira Diaz, Ana
  • Biagetti Biagetti, Betina
  • Camps-Relats, Laura
  • Cocera Rodriguez, Raul
  • Dopazo Taboada, Cristina
  • Fernandez Pujol, Andrea
  • Jimenez Hernandez, Cesar
  • Matarín Jiménez, Maria del Mar
  • Jofra, Mariona
  • Gil, Clara
  • Gomez Gavara, Concepción
  • Guevara Cubas, Jorge Alonso
  • Lobo Alvarez, Beatriz
  • Malagelada Prats, Carolina
  • Martínez Campreciós, Joan
  • Pando Rau, Elizabeth
  • Perez-Lopez, Ana
  • Prio, Alba
  • Rivera Esteban, Jesus Manuel
  • Romero, Alba
  • Tasayco Huaman, Stephanie Solange
  • Vidal Gonzalez, Judit
  • Vidal Piñeiro, Laura
  • Minguez Rosique, Beatriz
  • Genescà Ferrer, Joan
  • Ciudin Mihai, Andreea
  • Barber Caselles, Claudia
  • Augustin Recio, Salvador
  • Aguilera Castro, Lara
  • Guagnozzi, Danila
  • Miret Alomar, Enric
  • Pigrau Pastor, Marc
  • Mayorga Ayala, Luis Fernando
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Paràmetre d'atenuació controlat; Lesió hepàtica, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Parámetro de atenuación controlado; Daño hepático, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Controlled attenuation parameter; Liver injury, Liver injury has been widely described in patients with Coronavirus disease 2019 (COVID-19). We aimed to study the effect of liver biochemistry alterations, previous liver disease, and the value of liver elastography on hard clinical outcomes in COVID-19 patients. We conducted a single-center prospective observational study in 370 consecutive patients admitted for polymerase chain reaction (PCR)-confirmed COVID-19 pneumonia. Clinical and laboratory data were collected at baseline and liver parameters and clinical events recorded during follow-up. Transient elastography [with Controlled Attenuation Parameter (CAP) measurements] was performed at admission in 98 patients. All patients were followed up until day 28 or death. The two main outcomes of the study were 28-day mortality and the occurrence of the composite endpoint intensive care unit (ICU) admission and/or death. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were elevated at admission in 130 patients (35%) and 167 (45%) patients, respectively. Overall, 14.6% of patients presented the composite endpoint ICU and/or death. Neither ALT elevations, prior liver disease, liver stiffness nor liver steatosis (assessed with CAP) had any effect on outcomes. However, patients with abnormal baseline AST had a higher occurrence of the composite ICU/death (21% versus 9.5%, p = 0.002). Patients ⩾65 years and with an AST level > 50 U/ml at admission had a significantly higher risk of ICU and/or death than those with AST ⩽ 50 U/ml (50% versus 13.3%, p < 0.001). In conclusion, mild liver damage is prevalent in COVID-19 patients, but neither ALT elevation nor liver steatosis influenced hard clinical outcomes. Elevated baseline AST is a strong predictor of hard outcomes, especially in patients ⩾65 years., The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: JG is a recipient of a Research Intensification grant from the Instituto de Salud Carlos III, Spain. MST and MVC are recipients of a Juan Rodés grant from the Instituto de Salud Carlos III. The work was partially funded by grants PI17/00310, PI18/00947, PI18/00961, and PI19/00330 from Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF, “Investing in your future” – Una manera de hacer Europa). CIBERehd is supported by Instituto de Salud Carlos III. The work was independent of all funding.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Spontaneous portosystemic shunt embolization in liver transplant recipients with recurrent hepatic encephalopathy

  • Álvarez López, Patricia
  • Quiroga Gómez, Sergi
  • Díez Miranda, Iratxe
  • Charco Torra, Ramon
  • Simon-Talero Horga, Macarena
  • Castells Fusté, Lluis
  • Campos Varela, Isabel
Angiogenesis; Portal hypertension; Collateral vessels, Angiogénesis; Hipertensión portal; Vasos colaterales, Angiogènesi; Hipertensió portal; Vasos col·laterals, Introduction and objectives Spontaneous portosystemic shunts (SPSS) are a common cause of recurrent hepatic encephalopathy (HE). Shunt occlusion is an effective and safe procedure when performed in patients with cirrhosis and preserved liver function. We aimed to describe our experience with SPSS embolization after liver transplantation (LT). Patients We identified five patients who underwent SPSS embolization after LT. Clinical, biochemical and technical procedure data were collected. Results At presentation, all patients had developed graft cirrhosis and HE after LT. Median Model for End-stage Liver Disease (MELD) at embolization was 9 (range 7-12), median Child-Pugh was 8 (range 7-9). Splenorenal and mesocaval shunt were the most frequent types of SPSS found. Three patients have been completely free of HE. Of the two patients who had HE recurrence after embolization, one patient had two episodes of HE which was controlled well with medications. The other patient required three embolizations because of recurrent HE. Median follow-up was 4.4 years (range 1.0-5.0) and MELD score at last follow up was 13 (range 10-18) and median Child-Pugh score B, 7 points (range 5-12). Conclusions SPSS can be considered as a cause of HE after LT. SPSS embolization is feasible and safe in LT recipients., Isabel Campos-Varela's research activity is funded by grant PI19/00330, funded by Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF) - A way to build Europe. Macarena Simón-Talero is a recipient of the Juan Rodés grant JR17/00029 from Instituto de Salud Carlos III, Spain. CIBERehd is supported by Instituto de Salud Carlos III. The work was independent of all funding.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

High intrapatient variability of tacrolimus exposure associated with poorer outcomes in liver transplantation

  • Dopazo Taboada, Cristina
  • Bilbao Aguirre, Itxarone Izaskun
  • Gomez Gavara, Concepción
  • Caralt Barba, Mireia
  • Castells Fusté, Lluis
  • Moreso Mateos, Francesc
  • Montoro Ronsano, J. Bruno
  • Charco Torra, Ramon
  • Hidalgo Llompart, Ernest
  • Campos Varela, Isabel
  • García García, Sonia
Liver transplantation; Tacrolimus; Liver diseases, Trasplante de hígado; Tacrolimús; Enfermedades del hígado, Trasplantament hepàtic; Tacrolimús; Malalties del fetge, Tacrolimus (TAC) is a dose-dependent immunosuppressor with considerable intrapatient variability (IPV) in its pharmacokinetics. The aim of this work is to ascertain the association between TAC IPV at 6 months after liver transplantation (LT) and patient outcome. This single-center cohort study retrospectively analyzed adult patients who underwent transplantation from 2015 to 2019 who survived the first 6 months with a functioning graft. The primary end point was the patient’s probability of death and the secondary outcome was the loss of renal function between month 6 and the last follow-up. TAC IPV was estimated by calculating the coefficient of variation (CV) of the dose-corrected concentration (C0/D) between the third and sixth months post-LT. Of the 140 patients who underwent LT included in the study, the low-variability group (C0/D CV < 27%) comprised 105 patients and the high-variability group (C0/D CV ≥ 27%) 35 patients. One-, 3-, and 5-year patient survival rates were 100%, 82%, and 72% in the high-variability group versus 100%, 97%, and 93% in the low-variability group, respectively (p = 0.005). Moreover, significant impaired renal function was observed in the high-variability group at 1 year (69 ± 16 ml/min/1.73 m2 vs. 78 ± 16 ml/min/1.73 m2, p = 0.004) and at 2 years post-LT (69 ± 17 ml/min/1.73 m2 vs. 77 ± 15 ml/min/1.73 m2, p = 0.03). High C0/D CV 3–6 months remained independently associated with worse survival (hazard ratio = 3.57, 95% CI = 1.32–9.67, p = 0.012) and loss of renal function (odds ratio = 3.47, 95% CI = 1.30–9.20, p = 0.01). Therefore, high IPV between the third and sixth months appears to be an early and independent predictor of patients with poorer liver transplant outcomes., Isabel Campos-Varela’s research activity is funded by grant PI19/00330 from Instituto de Salud Carlos III. CIBERehd is supported by Instituto de Salud Carlos III. The work was independent of all funding.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

COVID-19 Clinical Profile in Latin American Migrants Living in Spain: Does the Geographical Origin Matter?

  • Sampol Sirvent, Julia
  • Espinosa Pereiro, Juan
  • Miarons Font, Marta
  • Bosch Nicolau, Pau
  • Guillen Del Castillo, Alfredo
  • Leguizamo-Martinez, Lina Maria
  • Oliveira Souto, Ines Mercedes
  • Almirante Gragera, Benito
  • Monforte, Arnau
  • Sempere González, Abiu
  • Campos Varela, Isabel
  • Aznar, María Luisa
  • Antón Pagarolas, Andrés
  • Salvador Velez, Fernando M
  • Sánchez Montalvá, Adrián
COVID-19; Latin America; Severity, COVID-19; Amèrica Llatina; Gravetat, COVID-19; América Latina; Gravedad, The aim of this study was to describe and compare the clinical characteristics of hospitalized patients with COVID-19 pneumonia according to their geographical origin. This is a retrospective case-control study of hospitalized patients with confirmed COVID-19 pneumonia treated at Vall d’Hebron University Hospital (Barcelona) during the first wave of the pandemic. Cases were defined as patients born in Latin America and controls were randomly selected among Spanish patients matched by age and gender. Demographic and clinical variables were collected, including comorbidities, symptoms, vital signs and analytical parameters, intensive care unit admission and outcome at 28 days after admission. Overall, 1080 hospitalized patients were registered: 774 (71.6%) from Spain, 142 (13.1%) from Latin America and the rest from other countries. Patients from Latin America were considered as cases and 558 Spanish patients were randomly selected as controls. Latin American patients had a higher proportion of anosmia, rhinorrhea and odynophagia, as well as higher mean levels of platelets and lower mean levels of ferritin than Spanish patients. No differences were found in oxygen requirement and mortality at 28 days after admission, but there was a higher proportion of ICU admissions (28.2% vs. 20.2%, p = 0.0310). An increased proportion of ICU admissions were found in patients from Latin America compared with native Spanish patients when adjusted by age and gender, with no significant differences in in-hospital mortality., Isabel Campos-Varela’s research activity is funded by grant PI19/00330 from Instituto de Salud Carlos III. CIBERehd is supported by Instituto de Salud Carlos III. The work was independent of all funding. This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.